To include your compound in the COVID-19 Resource Center, submit it here.

Data show Revlimid effective despite malignancy concerns

Celgene Corp. (NASDAQ:CELG) reported additional data from several trials that showed Revlimid lenalidomide is effective as maintenance therapy for multiple

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE